Merus NV (MRUS) Given Consensus Recommendation of “Hold” by Analysts

Merus NV (NASDAQ:MRUS) has earned an average rating of “Hold” from the eight analysts that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $24.80.

MRUS has been the topic of several analyst reports. Berenberg Bank initiated coverage on Merus in a research report on Wednesday, March 27th. They set a “buy” rating and a $35.00 target price on the stock. Citigroup cut their target price on Merus from $18.00 to $16.00 and set a “neutral” rating on the stock in a research report on Thursday, March 21st. BidaskClub raised Merus from a “strong sell” rating to a “sell” rating in a research report on Friday, March 1st. Wedbush cut their target price on Merus from $34.00 to $25.00 and set an “outperform” rating on the stock in a research report on Friday, April 5th. Finally, ValuEngine raised Merus from a “sell” rating to a “hold” rating in a research report on Wednesday, March 6th.

Shares of NASDAQ MRUS traded up $0.10 during midday trading on Thursday, hitting $13.66. 104,572 shares of the stock traded hands, compared to its average volume of 30,813. The company has a market cap of $327.84 million, a price-to-earnings ratio of -7.42 and a beta of -0.05. Merus has a one year low of $11.00 and a one year high of $26.74.



Merus (NASDAQ:MRUS) last released its quarterly earnings data on Wednesday, April 3rd. The biotechnology company reported ($0.34) EPS for the quarter. The firm had revenue of $9.67 million for the quarter. Merus had a negative net margin of 77.61% and a negative return on equity of 40.84%. On average, equities analysts expect that Merus will post -2.52 EPS for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. bought a new stake in shares of Merus during the 1st quarter valued at $79,000. BlackRock Inc. bought a new position in shares of Merus during the 1st quarter valued at about $131,000. Squarepoint Ops LLC increased its position in shares of Merus by 10.3% during the 4th quarter. Squarepoint Ops LLC now owns 11,800 shares of the biotechnology company’s stock valued at $165,000 after purchasing an additional 1,100 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Merus by 18.8% during the 4th quarter. Geode Capital Management LLC now owns 14,987 shares of the biotechnology company’s stock valued at $209,000 after purchasing an additional 2,373 shares during the last quarter. Finally, Renaissance Technologies LLC bought a new position in shares of Merus during the 1st quarter valued at about $236,000. 53.09% of the stock is currently owned by hedge funds and other institutional investors.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.

Featured Article: Cash Flow Analysis in Stock Selection

Analyst Recommendations for Merus (NASDAQ:MRUS)

Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.